Press releases
- Press releases
- Browse
Press releases
GenOdyssee S.A. announced today that the Journal of antimicrobial Agents and Chemotherapy (AAC*), has accepted a manuscript describing stronger and more sustained inhibitory effect of GenOdyssee's lead antiviral drug candidate, GEA007.1 More
The Wellcome Trust Limited and The Institute of Cancer Research announced a new alliance with GlaxoSmithKline to discover, develop and commercialize novel small molecule inhibitors of B-RAF for use as anti-cancer agent, More
With deals increasing in terms of number and value, partnering at early stage development is now an integral component of pharmaceutical and biotech business strategy. Pharmalicensing has revised and updated its successful Early Stage report More
Cancer Research Technology and The University of Manchester Announce Clinical Pharmacology Collaboration in Oncology with AstraZeneca More
Astex Therapeutics today announced that it had begun dosing first patients in a Phase I/IIa clinical trial of its investigational anti-cancer drug AT9283. More
Astex Therapeutics today announced that it has granted a non-exclusive, worldwide license to its Cytochrome P450 intellectual property to Pfizer Inc. More
Astex Therapeutics, one of Europe's premier biotechnology companies, today announced the appointment of Leon Bushara as its new Chief Executive Officer. More
Astex Therapeutics today announced a new drug discovery collaboration which will aim to identify small molecule inhibitors of the Fibroblast Growth Factor Receptor (FGFr) tyrosine kinase family. More
Astex Therapeutics today announced the approval of its Investigational New Drug (IND) application for the clinical development of its proprietary Aurora Kinase inhibitor, AT9283, for the treatment of cancer. More
These two patents cover natural mutants of human IFN alpha 17 and 21 among which are GenOdyssee's two lead IFN alpha products, GEA007.1 and GEA009.2 for application respectively as hepatitis C and immunotherapy treatments More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 19 pages - $99
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Your selection
Browse By
- Industry sector
- Bioinformatics
- Combinatorial biology
- Combinatorial chemistry
- Drug research platforms
- Genomics
- High throughput screening
- Proteomics
- Therapeutic target
- Anti-oxidant
- Bladder cancer
- Bone cancer
- Brain cancer
- Breast cancer
- Cancer (other)
- Cancer side effects
- Cervical cancer
- Colorectal cancer
- Head and neck cancer
- Kaposi's sarcoma
- Kidney cancer
- Leukemia
- Liver cancer
- Lung cancer
- Lymphoma
- Ovarian cancer
- Pancreatic cancer
- Polyps
- Prostate cancer
- Skin cancer
- Stomach/Esophageal
- Testicular cancer
- Transplant
- Treatments
- Tumor (other)
- Vaginal Cancer
- Womb cancer
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us